Opinion ID: 4517001
Heading Depth: 3
Heading Rank: 1

Heading: A method for preparing a deoxyribonucleic acid

Text: (DNA) fraction from a pregnant human female use- ful for analyzing a genetic locus involved in a fetal chromosomal aberration, comprising:
cell-free sample of blood plasma or blood se- rum of a pregnant human female to obtain extracellular circulatory fetal and mater- nal DNA fragments;
tracted in (a) by: Case: 19-1419 Document: 55 Page: 19 Filed: 03/17/2020 4 ILLUMINA, INC. v. ARIOSA DIAGNOSTICS, INC.
lar circulatory DNA fragments, and
fragments greater than approxi- mately 500 base pairs, wherein the DNA fraction after (b) comprises a plurality of genetic loci of the extracellular circulatory fetal and maternal DNA; and
of DNA produced in (b). Id. at col. 7 ll. 54–67, col. 8 ll. 53–57; cf., ’931 patent col. 7 ll. 58–67, col. 8 ll. 57–63 (claim 1). The dependent claims for each patent add detail such as techniques for conducting each method step and the detection of specific chromosomal aberrations. For example, claim 7 of the ’751 patent specifies centrifugation for the size discrimination step and claim 10 specifies for the detection of a fetal chromosomal aberration causing Down Syndrome. ’751 patent col. 9 ll. 1–2, 7–8.